ACOR Acorda Therapeutics, Inc.

20.70
-0.3  -1.43%
Previous Close 21.00
Open 21.05
Price To book 1.45
Market Cap 954.93M
Shares 46,132,000
Volume 776,759
Short Ratio 7.70
Av. Daily Volume 598,848

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17524457
  2. 8-K - Current report 17515720
  3. 8-K - Current report 162009042
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161979268
  5. 8-K - Current report 161953847

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Decision on Inter Partes Review (IPR) expected March 2017. Legal event (non-clinical).
Ampyra
Phase 2 to be initiated 1H 2017.
CVT-427
Migraine
Phase 3 data due 1Q 2018.
Tozadenant
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Dalfampridine
Post stroke deficits
Phase 3 data due 1Q 2017.
CVT-301
OFF episodes of Parkinson’s disease (PD)

Latest News

  1. Acorda Could Rival Lilly's 'Novel' Migraine Drug With Faster Onset
  2. Kura Oncology Starts Dosing Patients in Phase II CMML Study
  3. ACORDA THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
  4. Acorda Announces 2016 AMPYRA Net Sales and 2017 Financial Guidance at J.P. Morgan Healthcare Conference
  5. Post Earnings Coverage as Strongbridge Loss Narrowed; Acquires US Rights for KEYEVIS and Announced Equity Financing
  6. Acorda Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ACOR-US : January 5, 2017
  7. New year, new drug prices
  8. Acorda Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
  9. Acorda Therapeutics, Inc. – Value Analysis (NASDAQ:ACOR) : December 21, 2016
  10. Acorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : December 20, 2016
  11. Is Genomic Health, Inc. (GHDX) A Good Stock To Buy?
  12. These small-cap stocks are expected to rise at least 31% in 2017
  13. Is Kearny Financial (KRNY) A Good Stock To Buy?
  14. Acorda Therapeutics upgraded by JP Morgan
  15. Acorda Therapeutics Inc (ACOR) Continues To Fall From Favor With Top Investors
  16. Biotech Stock Roundup: Acorda Stops Ampyra PSWD Development, CRL for Spectrum's Qapzola
  17. Biotech Movers And Shakers: Mast Therapeutics, Inc. (MSTX) And Acorda Therapeutics Inc (ACOR)
  18. Acorda Stops Post-Stroke Development Program on Ampyra
  19. Acorda Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference
  20. In Case You Missed It Monday: Markets Punch Through Record Highs

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17524457
  2. 8-K - Current report 17515720
  3. 8-K - Current report 162009042
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 161979268
  5. 8-K - Current report 161953847
  6. UPLOAD [Cover] - SEC-generated letter
  7. CT ORDER - Confidential treatment order 161938434
  8. CORRESP [Cover] - Correspondence
  9. 8-K - Current report 161934063
  10. UPLOAD [Cover] - SEC-generated letter